The ME Association, a national charity based in Gawcott, Bucks, has announced its investment in a major clinical trial in Canada to study the effects of low-dose naltrexone (LDN) on ME, chronic fatigue syndrome (CFS) and Long Covid.
The trial, led by Dr. Luis Nacul at the University of British Columbia, will investigate whether LDN can alleviate symptoms like fatigue, pain, and sleep disturbances while reducing inflammation.
With no current cure for ME/CFS or Long Covid, the study aims to provide crucial evidence on LDN’s potential benefits. If successful, it could pave the way for wider use of the drug in the UK. Dr. Charles Shepherd, the ME Association’s medical advisor, emphasized the urgent need for effective treatments, highlighting the significant impact these conditions have on individuals and healthcare systems.
The double-blind, placebo-controlled trial is set to conclude by December 2025, with results expected in early 2026.
The ME Association in Bucks hopes this research will contribute to better treatment options for those suffering from these debilitating conditions.
Petition launched to introduce zebra crossing outside two Aylesbury schools
Rotary Club Donation Helps Young Carers Attend National Festival
Popular Knit & Natter Group Finds New Home in Aylesbury
Appeal for Witnesses After Serious Collision Near Winslow
Hundreds of nominations celebrated at 2026 Proud of Bucks Awards
Disqualified Driver Arrested on Suspicion of Cannabis Supply Offence in Aylesbury
Historic Walton Street Building Given New Lease of Life
New mayor of Aylesbury inaugurated at ceremony
